instruction
stringclasses 1
value | input
stringlengths 17
568
| output
stringlengths 1
80
|
|---|---|---|
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | Balint syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present a unique case of GTBM in a patient with myeloma following treatment with Melphalan. | Plasma cell myeloma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache. | Cerebral venous Thrombosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. | Interstitial lung disease |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. | Pneumonitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. | Pyrexia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Concomitant administration of lithium with olanzapine may place patients at risk for NMS. | Neuroleptic malignant syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. | Neuroleptic malignant syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Both 6-MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of thiopurine-induced hepatic injury. | Drug-induced Liver injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of 6-TG as a cause of liver enzyme abnormalities. | Liver function test abnormal |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a case of significant elevation of serum transaminases in a patient treated with 6-TG for a flare of Crohn's disease. | Transaminases increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure. | Multiple organ dysfunction syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and cyclophosphamide. | Hypogammaglobulinaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fulminant hepatic failure developed in a 24-year-old black woman who had been treated with propylthiouracil and propranolol for hyperthyroidism. | Acute hepatic failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. | Hepatitis fulminant |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug. | Drug-induced Liver injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine. | Hypothermia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This is a case report of subtle, mild hypothermia in a 54-year old female patient receiving risperidone for schizophrenia. | Hypothermia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Clozapine-induced akathisia in children with schizophrenia. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After reviewing the literature we suggest the CPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced blindness. | Blindness |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Central pontine myelinolysis manifested by temporary blindness: a possible complication of lithium toxicity. | Osmotic demyelination syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ). | Hepatic enzyme increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report. | Hepatic function abnormal |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Interferon-alpha (IFN-alpha) may precipitate or exacerbate the occurrence of MPGN. | Hepatic function abnormalImmune-complex membranoproliferative glomerulonephritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Minimal change disease in a patient receiving IFN-alpha therapy for chronic hepatitis C virus infection. | Glomerulonephritis minimal lesion |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr. | Chronic myeloid leukaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. | Philadelphia positive Chronic myeloid leukaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea. | Chronic myeloid leukaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole. | Pyrexia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor. | Agranulocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). | Agranulocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Comeoscleral perforation after pterygium excision and intraoperative mitomycin C. | Corneal perforation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported. | Corneal perforation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 71-year-old man, who had a history of a previous bullous drug reaction to a sulfonamide, began receiving an ophthalmic preparation that contained sulfacetamide sodium. | Drug eruption |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The patient received only the ophthalmic sulfonamide, and it was used for one day, but he developed Stevens-Johnson syndrome. | Stevens-Johnson syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The sulfonamides are the best verified drug-trigger for erythema multiforme and Stevens-Johnson syndrome. | Erythema multiforme |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride. | Diabetes insipidus |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Treatment of lithium-induced diabetes insipidus with amiloride. | Diabetes insipidus |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF). | Granulocyte-colony stimulating factor level increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously. | Kawasaki's disease |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before neurologic abnormalities began. | Immune-mediated neurological disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss. | Aphasia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Tacrolimus (FK506), an immunosuppressant, has been associated with mutism in adults after liver transplant. | Mutism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Tacrolimus (FK506)-induced mutism after liver transplant. | Mutism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema? | OOedema |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion. | Ascites |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of insulin (> 110 units/day), suggesting the existence of insulin insensitivity and hyperinsulinaemia. | Hyperinsulinaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Intrathecal methotrexate-induced acute cerebellar syndrome. | Cerebellar syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously. | Cerebellar syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration. | Angioimmunoblastic T-cell lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration. | Angioimmunoblastic T-cell lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Anaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Isoniazid-induced anaphylaxis. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy. | Hypoparathyroidism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Carbamazepine-related hyponatremia following cardiopulmonary bypass. | Hyponatraemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We discuss the association between carbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass. | Hyponatraemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After 5-ASA was discontinued, the polyneuropathy symptoms recovered gradually. | PolyNeuropathy peripheral |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report. | Peripheral sensorimotor Neuropathy peripheral |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA. | Peripheral sensorimotor Neuropathy peripheral |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. | Atrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris. | Cryptococcosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP. | Lymphocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. | Infectious mononucleosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP). | Infectious mononucleosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a lupus-like syndrome eight months after her initial infusion. | Lupus-like syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A lupus-like syndrome associated with infliximab therapy. | Lupus-like syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent. | Lupus-like syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report in detail an unusual adverse reaction to infliximab therapy, a drug-induced lupus-like clinical syndrome. | Lupus-like syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (IFNalpha) have all been associated with renal dysfunction. | Renal tubular dysfunction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Despite the underlying hepatitis C, this case represents renal abnormalities consistent with IFNalpha therapy for CML. | Renal disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature. | Focal segmental glomerulosclerosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The renal biopsy showed focal segmental glomerulosclerosis, which has only been previously reported in two cases of CML treated with IFNalpha. | Focal segmental glomerulosclerosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. | Autoimmune haemolytic Anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab. | B-cell depletion therapy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia. | Autoimmune haemolytic Anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report. | Myelitis transverse |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination. | Quadriparesis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Although it would be expected that, like other type IA toxicities, diphenhydramine-induced cardiotoxicity could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated. | Cardiotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. | Arrhythmia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, because diphenhydramine also exhibits type IA sodium channel blockade, cardiac toxicity is also possible. | Cardiotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe 3 cases of diphenhydramine-induced cardiac toxicity that were responsive to bicarbonate. | Cardiotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a patient with extranodal non-Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide-based chemotherapy regimen. | Systemic candida |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy. | Stevens-Johnson syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks. | SJS-Toxic epidermal necrolysis overlap |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented. | Leprosy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, in order to avoid neuropathic side effects, patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug. | Neuropathy peripheral peripheral |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations. | Diabetic Neuropathy peripheral |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C. | Optic neuritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia. | Optic neuritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSIONS: Optic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural interferon alpha administration. | Neurological symptom |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Multiple sclerosis-like disease secondary to alpha interferon. | Autoimmune demyelinating disease |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration. | Optic neuritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen. | Acute abdomen |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery. | Endometriosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient. | Agranulocytosis |